Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CEO Joshua B. Cohen sold 21,490 shares of the company's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $74,570.30. Following the sale, the chief executive officer now directly owns 3,355,280 shares in the company, valued at $11,642,821.60. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Amylyx Pharmaceuticals Price Performance
NASDAQ AMLX traded up $0.03 during trading hours on Monday, reaching $3.46. 1,168,275 shares of the stock traded hands, compared to its average volume of 1,347,684. The stock has a 50 day simple moving average of $3.55 and a two-hundred day simple moving average of $4.07. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $7.27. The company has a market cap of $306.56 million, a price-to-earnings ratio of -0.91 and a beta of -0.53.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The company had revenue of ($0.67) million during the quarter. On average, sell-side analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on AMLX. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Mizuho upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $3.00 to $7.00 in a research note on Monday. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.
View Our Latest Analysis on Amylyx Pharmaceuticals
Institutional Investors Weigh In On Amylyx Pharmaceuticals
A number of institutional investors have recently made changes to their positions in AMLX. Boxer Capital Management LLC bought a new stake in Amylyx Pharmaceuticals in the fourth quarter worth $6,615,000. Bank of America Corp DE lifted its stake in shares of Amylyx Pharmaceuticals by 165.9% in the 4th quarter. Bank of America Corp DE now owns 2,426,263 shares of the company's stock valued at $9,171,000 after acquiring an additional 1,513,748 shares during the last quarter. Walleye Capital LLC lifted its stake in shares of Amylyx Pharmaceuticals by 986.5% in the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company's stock valued at $2,173,000 after acquiring an additional 608,874 shares during the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Amylyx Pharmaceuticals by 862.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 472,397 shares of the company's stock valued at $1,786,000 after acquiring an additional 423,316 shares during the period. Finally, Jane Street Group LLC grew its position in Amylyx Pharmaceuticals by 122.4% during the 4th quarter. Jane Street Group LLC now owns 765,475 shares of the company's stock worth $2,893,000 after acquiring an additional 421,302 shares during the last quarter. Hedge funds and other institutional investors own 95.84% of the company's stock.
Amylyx Pharmaceuticals Company Profile
(
Get Free Report)
Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.
Featured Articles
Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
